(Q31805135)

3 July 2017

1 reference

title

Oral glycoprotein IIb/IIIa antagonists in coronary artery disease (English)

1 reference

3 July 2017

main subject

coronary artery disease

1 reference

Chew DP

1

1 reference

3 July 2017

Bhatt DL

series ordinal

2

1 reference

3 July 2017

publication date

1 January 2001

1 reference

Current cardiology reports

3 July 2017

published in

1 reference

3 July 2017

volume

3

1 reference

3 July 2017

issue

1

1 reference

3 July 2017

page(s)

63-71

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-001-0012-2

3 July 2017

exact match

0 references

cites work

Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0012-2

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0012-2

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0012-2

Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0012-2

Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.

21 January 2018

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

12 December 2020

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute

1 reference

12 December 2020

Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

1 reference

12 December 2020

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

12 December 2020

Platelet GPIIb-IIIa blockers

1 reference

12 December 2020

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

12 December 2020

Current concepts of thrombosis.

1 reference

12 December 2020

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction

1 reference

12 December 2020

Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors

1 reference

12 December 2020

Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction

1 reference

12 December 2020

RGD peptides induce apoptosis by direct caspase-3 activation.

1 reference

12 December 2020

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

12 December 2020

Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses

1 reference

12 December 2020

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

12 December 2020

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

12 December 2020

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

1 reference

12 December 2020

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

12 December 2020

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM

1 reference

12 December 2020

Ligand inhibition of the platelet glycoprotein IIb-IIIa complex function as a calcium channel in liposomes

1 reference

12 December 2020

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

12 December 2020

Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists

1 reference

12 December 2020

Platelet hyperreactivity and prognosis in survivors of myocardial infarction

1 reference

12 December 2020

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention

1 reference

12 December 2020

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

12 December 2020

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

12 December 2020

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

1 reference

12 December 2020

Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial

1 reference

12 December 2020

Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin

1 reference

12 December 2020

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

1 reference

12 December 2020

10.1007/S11886-001-0012-2

Identifiers

DOI

1 reference

Dimensions Publication ID

3 July 2017

1021480359

0 references

1 reference